Back to top
more

TFF Pharmaceuticals (TFFP)

(Delayed Data from NSDQ)

$1.84 USD

1.84
53,571

-0.06 (-3.16%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $1.84 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of 28.24% and 333.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 12.50% and 0.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 26.89% and 75.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of -9.09% and 35.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 66.27% and 315.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 41.98% and 96.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 37.50% and 173.49%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -0.89% and 40.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -80% and 96.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 1.59% and 157.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Acquire New CDMO Facility for $475 Million

by Zacks Equity Research

Catalent (CTLT) agrees to buy Mayne Pharma's specialty CDMO division, Metrics Contract Services, for $475 million. The deal is expected to be completed by 2022-end.

Wall Street Analysts Think TFF Pharmaceuticals, Inc. (TFFP) Could Surge 233%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for TFF Pharmaceuticals, Inc. (TFFP) points to a 233.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TFF Pharmaceuticals, Inc. (TFFP) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -33.33% and 98.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

by Zacks Equity Research

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

TFF Pharmaceuticals, Inc. (TFFP) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -142.86% and -97.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.

New Strong Sell Stocks for July 8th

by Zacks Equity Research

CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021

New Strong Sell Stocks for June 28th

by Zacks Equity Research

BNL, CANG, TFFP, AJRD and SJW have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2021.

Why Earnings Season Could Be Great for TFF Pharmaceuticals (TFFP)

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Turtle Beach (HEAR) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Turtle Beach's (HEAR) fourth-quarter 2020 earnings are likely to have benefited from operational execution in a strong market for gaming accessories.